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Abstract
Background: Several linkage studies suggest that chromosome 5q31-32 might contain risk loci for
schizophrenia (SZ). We wanted to identify susceptibility genes for schizophrenia within this region.
Methods: We saturated the interval between markers D5S666 and D5S436 with 90 polymorphic
microsatellite markers and genotyped two sets of DNA pools consisting of 300 SZ patients of
Bulgarian origin and their 600 parents. Positive associations were followed-up with SNP genotyping.
Results: Nominally significant evidence for association (p < 0.05) was found for seven markers
(D5S0023i, IL9, RH60252, 5Q3133_33, D5S2017, D5S1481, D5S0711i) which were then
individually genotyped in the trios. The predicted associations were confirmed for two of the
markers: D5S2017, localised in the SPRY4-FGF1 locus (p = 0.004) and IL9, localized within the IL9
gene (p = 0.014). Fine mapping was performed using single nucleotide polymorphisms (SNPs)
around D5S2017 and IL9. In each region four SNPs were chosen and individually genotyped in our
full sample of 615 SZ trios. Two SNPs showed significant evidence for association: rs7715300 (p =
0.001) and rs6897690 (p = 0.032). Rs7715300 is localised between the TGFBI and SMAD5 genes and
rs6897690 is within the SPRY4 gene.
Conclusion: Our screening of 5q31-32 implicates three potential candidate genes for SZ: SMAD5,
TGFBI and SPRY4.
Background
Schizophrenia (SZ) is a common, severe and disabling
disorder that in most cases requires a long-term medical
and social care. The lifetime risk for SZ in the population
worldwide is around 1%. Family, adoption and twin stud-
ies have shown conclusively that a genetic component
plays the most important role in its aetiology [1]. At
present, the number of susceptibility loci, the disease risk
conferred by each locus and the degree of interaction
between them remain unknown [2]. The mode of trans-
mission is complex and non-Mendelian and is probably
contributed by a small number of genes of moderate
effect, or by many genes of small effect, or a mixture of the
two [3].
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In the present study we investigated one strong region of
linkage to schizophrenia: 5q31-32. This region emerged
as one of the five most consistent regions in a meta-anal-
ysis of the genome-wide linkage studies [4]. The main
linkage findings for 5q23-33 are summarised in Figure 1.
We concentrated upon a minimal region of interest
between markers D5S666 and D5S436 as it includes five
of the regions showing linkage to schizophrenia [5-9]. We
decided to concentrate on this region, rather than on the
full region, as it is the most likely region to contain suscep-
tibility genes, due to the concentration of five linkage
findings. We would have been unable to provide similar
dense coverage of the whole interval with the funding we
received for this project. This interval is ~14 Mb long and
contains ~330 genes (UCSC built 35, May 2004), of
which 52 constitute the protocadherin α, β, γ clusters. Pro-
tocadherins are expressed throughout the nervous system
and are involved in synapse formation, specification and
maintaining, which make them potential candidate genes
for schizophrenia. This group of genes and their relation
to schizophrenia has being investigated by several
research groups [10-13]. Other promising candidate genes
in this region are NRG2  (Neuregulin 2) and IL9  (P40
cytokine). The neuregulins are a family of growth and dif-
ferentiation factors with a wide range of functions in the
nervous system [14]. Neuregulin signalling plays an
important role in many neurological disorders including
multiple sclerosis, traumatic brain and spinal cord injury,
peripheral neuropathy, and possibly schizophrenia [14-
16]. According to the glial growth factors deficiency and
synaptic destabilization hypothesis of SZ, functional defi-
ciency of glial growth factors and of growth factors such as
neuregulin, insulin-like growth factor I, insulin, epider-
mal growth factor, neurotrophic growth factors, erbB
receptors and others, are among the distal causes in the
genotype-to-phenotype chain leading to the development
of SZ [17]. Cytokines are key molecules regulating
immune/inflammatory reactions. They are involved in
brain development, regulation of dopaminergic and
GABAergic differentiation, and synaptic maturation. Cer-
tain cytokines are postulated to have a central role in the
neurodevelopmental defects in SZ [18,19].
The systematic association analysis of complex disorders
requires genotyping of numerous genetic markers over
particular genomic regions, or more recently the entire
genome, in large samples. The cost of such studies is pro-
hibitive for most laboratories. DNA pooling is a way to
decrease the cost, time and labour that are involved in a
large-scale genotyping [20]. Briefly, in DNA pooling equi-
molar amounts of DNA are taken from each individual
mixed to form two sets of pools, cases and controls. Pre-
dicted allele frequencies are then estimated on the basis of
the intensities produced in each pool. DNA pooling is
capable of detecting loci with small effect sizes and
decreases the cost of the analysis by orders of magnitude.
The power of pooling studies is approximately the same as
for individual genotyping of affected and non-affected
individuals, with a mean error rate of pooled analysis
reported for different pooling techniques in the region of
<2% [20-23].
In the present study, the initial DNA pooling and individ-
ual genotyping was performed using microsatellite mark-
ers, and fine mapping was performed with single
nucleotide polymorphisms (SNPs). We reasoned that
microsatellite markers have several advantages over SNPs
for initial screening: they are highly polymorphic with
corresponding high degree of heretozygosity (on average
~70%) and they can detect linkage disequilibrium (LD)
over larger distances than SNPs (~100 kb range compared
to ~30 kb range for SNPs) [24,25] probably due to the fact
that they have a high mutation rate, making it possible for
Linkage findings in schizophrenia in the 5q23-33 region Figure 1
Linkage findings in schizophrenia in the 5q23-33 
region. Straub et al (1997) [5] reported a maximum LOD 
score of 3.04 for schizophrenia at D5S393. Schwab et al 
(1997) [6] reported maximum LOD score of 1.8 for the 
marker IL9 by two point lod score analysis. Paunio et al 
(2001) [7] obtained a maximum lod score of 3.56 at D5S414. 
Gurling et al (2001) [50] reported a LOD score 3.6 at 
D5S422. Devlin et al (2002) [8] reported a LOD score of 3.4 
at D5S1480 and Sklar et al (2004) [9] obtained a NPL score 
of 3.09 (p = 0.0012) at D5S820.BMC Psychiatry 2008, 8:11 http://www.biomedcentral.com/1471-244X/8/11
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certain of their alleles to capture associations of more
recent origin. Therefore, we reasoned that we could cover
the 14 Mb interval with fewer microsatellite markers, than
with SNPs, thus making it possible to conduct the study
within the budget of our research project.
We chose to use an initial screening step of applying
pooled analysis to polymorphic microsatellite spanning
5q31-32, and a follow up stage of individual genotyping
in the same samples from which the pools were con-
structed for markers showing nominally significant evi-
dence for association (p < 0.05). SNPs in regions
containing a confirmed nominally significant microsatel-
lite marker (p < 0.05) were then examined further for




For the initial screen, we used two parent-proband DNA
pools: one from 300 SZ patients and the second one from
their 600 parents. All trios are of Bulgarian origin. They
were either inpatients from five different psychiatric hos-
pitals, or outpatients from four of the largest psychiatric
dispensaries in Bulgaria. All had a history of hospitaliza-
tion for a schizophrenic episode. Each proband was inter-
viewed with an abbreviated version of the SCAN
instrument (Schedules for Clinical Assessment in Neu-
ropsychiatry) [26]. Consensus best-estimate diagnoses
were made according to DSM-IV criteria (Diagnostic and
Statistical Manual of Mental Disorders, 4th edn.1994) [27]
by two raters using information from the interview and
hospital notes. All patients included in the study met
DSM-IV criteria for schizophrenia. Local ethics committee
approval was obtained from all the regions where patients
were recruited. All patients and their parents were given
information sheets and provided written informed con-
sent for participation in genetic association studies. DNA
was extracted by standard phenol-chloroform method
from peripheral blood. The selected microsatellite mark-
ers for individual genotyping were genotyped in the same
sample of 300 trios families that were included in the
pools, while the SNPs were genotyped in the full sample
of 615 SZ trios that have been recruited by the team in
Bulgaria. To inform our choice of SNPs for fine-mapping,
we used data from another pooling study on 574 SZ trios
(explained in more detail below). This larger pool
includes the original pool of 300 trios used in the main
microsatellite study, and a second pool of 274 trios from
our full sample of 615 trios.
Choice of markers
Microsatellites
Microsatellite markers were selected from JBIRC database
[28], developed on the basis of analysis of microsatellite
markers covering the whole human genome [25], and the
UCSC Genome Browser (built 35, May 2004) [29]. We
aimed to place markers at an average density of one every
~100 kb. We first selected validated polymorphic markers
within our region of interest using all available informa-
tion from JBIRC. In cases where the distance between val-
idated markers was greater than 100 kb, we selected non-
validated di-, tri- tetra- and penta-nucleotide repeats from
UCSC and validated them ourselves by examining
whether they were polymorphic. We selected a total of
140 microsatellite markers from the two databases. 50
markers were not included in the analysis because they
produced heavy stutter bands or were not polymorphic.
We successfully analysed 90 markers, of which 24 were
chosen from JBIRC and 66 from UCSC database (39 are
novel markers that have not been validated before). The
average distance between the analysed 90 polymorphic
markers was ~150 kb and 72% of the microsatellite mark-
ers were di-nucleotide repeats, the remaining were tri-,
tetra- or penta-nucleotide repeats.
SNPs
In order to improve our chances of identifying the most
significant SNPs around significant microsatellites for the
fine mapping, we selected SNPs from the pooling data of
a genome-wide association (GWA) study of schizophrenia
in the same Bulgarian trios, conducted by the Department
of Psychological Medicine, Cardiff University towards the
end of the microsatellite project (manuscript in press)
[30]. The results of the study on Illumina arrays became
available just at the time when we started selecting SNPs
for fine mapping. We wanted to saturate an extended area
of ~400 kb around positive microsatellites, in order to
identify the peak of the maximum significance in each
region. The latest versions of the HapMap database con-
tain hundreds of SNPs in these regions, making it impos-
sible for us to provide dense coverage with the funding
available. This is why we decided to make use of our Illu-
mina data. We reasoned that SNPs which are not signifi-
cantly associated in that study of overlapping samples,
were most likely to remain negative after individual geno-
typing, therefore we could only target those SNPs that pro-
duced significant results (at a predicted p-value of ≤ 0.05).
The GWA pooling study was carried out with Illumina
HumanHap550 Genotyping BeadChip technology using
pooled DNA from 574 SZ patients and a pool from all the
parents of the cases [30]. The pool of 574 trios includes
the pool of 300 trios prepared for the microsatellite asso-
ciation study, plus an additional pool of 274 SZ trios that
was prepared from the available SZ trios recruited by our
team in Bulgaria. Although the complete number of trios
available for individual genotyping was 615, only 574
trios are included in the pools, for the following reasons.
1) A small number of samples had lower DNA concentra-
tion, making them unsuitable for pooling. 2) A number ofBMC Psychiatry 2008, 8:11 http://www.biomedcentral.com/1471-244X/8/11
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families are multiply affected, providing more than one
trio for the analysis of individual genotyping. However,
only one trio per family was included in pools.
Genotyping
For microsatellites we designed flanking primers labelled
at their 5' end with a fluorescent dye. PCR primers were
designed with the Primer 3 program [31]. All primers were
checked with BLAT in order to make sure their sequences
were unique. Fragments were amplified using a standard
PCR touch-down protocol on thermal cycler DNA Engine
Tetrad machines (MJ Research, USA). Fragments were sep-
arated on an ABI3100 capillary sequencer (Applied Bio-
systems, USA). Microsatellite markers for individual
genotyping were amplified in a multiplex PCR reaction
using the same protocol as above.
SNPs were genotyped using the Sequenom MassARRAY™
iPlex™ chemistry (Sequenom, San Diego, California, USA)
[32] or Amplifluor™ SNP Genotyping Systems (Serologi-
cals Corporation, USA) [33,34] according to the recom-
mendations of the manufacturers.
Pooled DNA genotyping
The principles of pooled DNA genotyping have been
described before [21,22]. Briefly, an equimolar amount of
DNA was taken from every individual from one sample
set and put into a single tube (one pool). The DNA from
every sample was quantified using the PicoGreen ds DNA
Quantification Reagent (Molecular Probes, Eugene, Ore-
gon, USA). Each pooled DNA was amplified in triplicate
and the PCR products were separated on an ABI3100 cap-
illary sequencer. If any of the replicates gave more than
3% difference in any one allele, the experiment was
repeated, or this replicate excluded. The peak heights of
the signal representing each of the alleles were measured
using GENOTYPER 2.5 software. The peak heights were
used to estimate the relative allele frequencies in the
pools, assuming that peak height is directly proportional
to the concentration of that allele in the pool. Thus, the
allele frequencies were estimated from the peak height for
each allele divided by the sum of the peak heights for all
alleles. We didn't apply correction for stutter bands and
differential amplification, as described before [21].
Statistical analysis
For analysis of pooling results we used the CLUMP pro-
gram [35] to compare the predicted allele frequencies of
probands with the non-transmitted parental alleles (our
pseudo-controls). For each marker we ran 1000 simula-
tions and estimated the nominal p-value. Individual gen-
otyping results were analyzed with the Extended
Transmission Disequilibrium Test (ETDT) for multiallelic
markers and the Transmission Disequilibrium Test for
SNPs [36-38]. Analyses of linkage disequilibrium (LD)




We designed and genotyped 140 microsatellite markers
covering a region of ~14 Mb (between markers D5S666
and D5S436, Figure 1) in parents and probands pools.
After excluding non-polymorphic markers and those pro-
ducing heavy stutter bands, we successfully analysed 90
polymorphic microsatellite markers. Seven markers
showed suggestive evidence for association with SZ (p <
0.05) and were selected for individual genotyping. These
were D5S0023i (p = 0.033), IL9 (p = 0.046), RH60252 (p
= 0.041), 5Q31-33_33 (p = 0.031), D5S2017 (p = 0.013),
D5S1481 (p = 0.030), D5S0711i (p = 0.028). In order to
confirm the results from the pooling experiment, we per-
formed individual genotyping of these markers in the
sample of 300 parent-proband trios that were included in
the pools. Results from individual genotyping are pre-
sented in Table 1. Marker D5S0023i could not be ana-
lyzed as it produced heavy stutter bands, making allele
calling unreliable. Two markers remained nominally sig-
nificant after the individual genotyping: marker IL9 (p =
0.014), located within the IL9 (interleukin 9 precursor)
gene and marker D5S2017 (p = 0.004), located 28.5 kb 3'
from the SPRY4 (Sprouty homolog 4) gene. The distance
between the two markers is approximately 6.5 Mb.
Table 1: Pooling and individual genotyping results for microsatellite markers showing suggestive evidence for association.
# Marker name Position in bp 
(UCSC May, 04)
Repeat type Number of 
repeats
Pooling p-value Individual genotyping 
p-value
1 D5S0023i chr5:133235407–133235452 AAGG 9 0.033 no data
2 IL9 chr5:135256322–135256367 AC 12 0.046 0.014
3 RH60252 chr5:139324127–139324160 AC 11 0.041 0.51
4 5Q31-33_33 chr5:141503743–141503777 TAA 6 0.031 0.10
5 D5S2017 chr5:141713613–141713660 TG 6 0.013 0.004
6 D5S1481 chr5:144559890–144559927 TAT 10 0.030 0.77
7 D5S0711i chr5:145722795–145722839 AAACA 9 0.028 0.99BMC Psychiatry 2008, 8:11 http://www.biomedcentral.com/1471-244X/8/11
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SNPs
In order to further investigate the two candidate regions,
we performed fine mapping using SNPs. Eight SNPs were
selected from regions of 400 kb surrounding the micros-
atellites D5S2017 and IL9 from the data of our GWA study
in 574 SZ trios carried out in the same population (see
Methods). These eight SNPs had shown suggestive signif-
icance for association (p = 0.05) in the pooling data.
Rs17169180, rs1859430, rs30747 and rs7715300 are
around the IL9 area, and rs2961720, rs7443175,
rs6897690 and rs153423 are from the D5S2017 area (Fig-
ures 2 and 3). We could not produce a robust assay for
genotyping rs2961720, so we substituted it with
rs2906066 which was in complete LD with rs2961720 (r2
= 1) in the CEU trios sample (Utah residents with ancestry
from Northern and Western Europe) from HapMap [41].
Results from the individual genotyping are presented in
Table 2.
Individual genotyping in the total sample of 615 parent-
proband trios confirmed one SNP in each region as signif-
icantly associated with SZ: rs7715300 (p = 0.001) and
rs6897690 (p = 0.032). One more SNP in each region
approached significance (p = 0.06). Rs7715300 is located
between two genes: 30 kb 3'of TGFBI (transforming
growth factor, beta-induced, 68 kDa) and 39.5 kb 5' of
SMAD5 (SMAD, mothers against DPP homolog 5).
Rs6897690 is located in intron1 of SPRY4 (sprouty
homolog 4). All markers were in Hardy-Weinberg equilib-
rium. No significant linkage disequilibrium (LD) between
the studied SNPs was observed (r2 < 0.1). In order to pro-
vide the full information, we also present in the Table the
p-values provided by the 300 trios in the original pools
used for the microsatellite study, which demonstrate
some fluctuation from those in the full sample.
Discussion
Pooling is a fast and cost-effective approach used for sys-
tematic screening of complex disease associations, where
many markers need to be genotyped in large samples. The
power of pooling is approximately the same as individual
genotyping and has proved to be an accurate method for
detecting allele differences using microsatellite markers or
SNPs, with a mean error of <2% for the pooled analysis
[21-23,42,43].
In the present study we wanted to investigate the chromo-
somal region 5q31.1-q32 between markers D5S666 and
D5S436 because it includes five reported linkage regions
for SZ [5-9] and a number of good candidate genes. We
started with saturating the 14 Mb region with microsatel-
lite markers using DNA pooling, an approach proven suc-
cessful for other complex diseases [25,44,45]. Based on
the knowledge that the average length of LD around mic-
rosatellite markers is approximately 100 kb, we covered
the region with 140 microsatellite markers of which 90
turned out to be polymorphic and gave reliable traces. We
found a suggestive evidence for association with SZ for
seven markers. Individual genotyping confirmed two of
them to be significantly associated: D5S2017 (p = 0.004)
Markers and genes in the region around IL9 marker Figure 2
Markers and genes in the region around IL9 marker. Included are base pair position according to UCSC built 35, May 
2004, chromosome band, gene and the genotyped SNPs and microsatellite markers within the region.
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Markers and genes in the region around D5S2017 marker Figure 3
Markers and genes in the region around D5S2017 marker. Included are base pair position according to UCSC built 35, 
May 2004, chromosome band, gene and the genotyped SNPs and microsatellite markers within the region.
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Table 2: Summarized individual genotyping results for SNPs and TDT results.
SNP ID Position Gene 
name▲






T/NT χ2 Individual genotyping 
total sample p-value
Individual genotyping 
300 trios pool p-value
rs17169180 135188954 LOC153328 C/A 0.008 613 0.14 0.15 142/176 3.64 0.06 0.20
rs1859430 135258412 IL9 T/C 0.04 599 0.19 0.20 177/203 1.78 0.18 0.14
rs30747 135366739 TGFBI C/A 0.04 590 0.05 0.05 60/58 0.03 0.85 0.28
rs7715300 135456919 TGFBI C/A 0.03 612 0.06 0.08 64/108 11.26 0.001 0.18
rs2906066 141560461 - T/C 0.05 589 0.14 0.13 122/145 1.98 0.16 0.57
rs7443175 141675612 SPRY4 T/C 0.03 612 0.23 0.25 239/200 3.46 0.06 0.36
rs6897690 141681136 SPRY4 A/G 0.008 615 0.22 0.24 255/209 4.56 0.03 0.0006
rs153423 141794129 - C/T 0.05 611 0.21 0.20 180/202 1.27 0.26 0.46
▲  Gene names are given for the intragenic SNPs and SNPs within 30 kb of a gene (column 3,"Gene name").
* Minor allele is always presented first and its frequencies in children and in parents are given in columns 7 and 8 ("Frequency children", "Frequency parents"). Transmission/non-transmission 
counts from heterozygous parents for the minor allele in each case are in column 9 ("T/NT"). P-values from Transmission Disequilibrium Test (TDT) for the total sample and the pool sample are 
given in the column 11 ("Individual genotyping total sample p-value") and column 12 ("Individual genotyping 300 trios pool p-value"). Predicted pooling p-values are presented in column 5, 
("Pooling p-value"). Pooling p-value is also provided for rs2906066, although it is not on the array, because it is in complete LD with rs2961720 which produced that p-value. All markers were in 
Hardy-Weinberg equilibrium.BMC Psychiatry 2008, 8:11 http://www.biomedcentral.com/1471-244X/8/11
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and IL9 (p = 0.014). Marker IL9 is located within the IL9
gene and is the same microsatellite previously reported by
Schwab et al [6] to produce a max LOD score of 1.8 in 14
SZ pedigrees.
We then performed fine mapping with SNPs within an
area of ~400 kb surrounding the IL9 and D5S2017 micro-
satellites. In order to improve our chances of identifying
significant association, we chose to genotype only prom-
ising SNPs from another pooling study in SZ on Illumina
HumanHap550 arrays [30]. That study used an extended
sample of 574 Bulgarian trios and was finished just at the
time when we were selecting SNPs to follow-up (all 300
trios used in the microsatellite stage of the study were part
of that larger sample). We selected 8 SNPs (4 for each
region), that had shown nominal significance (p = 0.05)
in pools hybridised on Illumina arrays. This considerably
reduced the cost of our project, as the two regions con-
tained nearly 200 SNPs on the Illumina arrays (and even
more in the HapMap database). Individual genotyping of
the SNPs in the full 615 parent-proband trios confirmed
the pooling results for two SNPs: rs7715300 (p = 0.001)
and rs6897690 (p = 0.032). SNPs rs17169180 and
rs7443175 showed only trends toward association (p =
0.06). To show the validity of the pooling approach, we
also report data on the 300 trios in our original pools in
the Table 2. However our aim was to identify susceptibil-
ity loci for SZ which is clearly best achieved by genotyping
as large a sample as possible, therefore the full data on the
615 trios constitutes our primary analysis.
Clearly, the strongest signal identified in our study is at
rs7715300, located between two genes: 30 kb 3'of TGFBI
and 39.5 kb 5' of SMAD5 (Figure 2). We cannot speculate
whether rs7715300 is a causal variant itself, or it is in LD
with a marker within any of the two genes (however no
SNP within the two genes is in high r2 with rs7715300). A
Bonferroni correction for 90 microsatellite markers and 8
SNPs, would however make this result not significant (p =
0.1) indicating the need for replication in other samples,
especially from populations that have shown linkage to
this region. No Bulgarian sample has been investigated for
linkage to SZ, and we don't know if linkage to 5q is
present in that population.
SMAD proteins are intracellular mediators in the bone
morphogenetic proteins (BMPs) signalling pathway.
SMADs are the only known BMP receptor substrates capa-
ble of signal transduction. Activated by phosphorilation
SMADs move to the nucleus where they assemble com-
plexes directly involved in the control of gene expression.
SMAD5 is expressed in early differentiated granule neu-
rons of the developing cerebellar cortex. BMP2 signalling
activity is directly mediated by SMAD5 and its expression
is sufficient to trigger granule cell precursor differentiation
[46,47]. It can be speculated that dysfunctional SMAD
genes can cause disruption in BMP signalling pathway
which is directly linked to the transcriptional control of
the oligodendrogenesis [48].
Defects in TGFBI are the cause of several types of corneal
dystrophies. TGFBI protein binds to different types of col-
lagen and is important for the cell- collagen interactions
in cartilage. The function of the protein and its low expres-
sion in the brain make TGFBI a less plausible candidate
gene for schizophrenia [49].
The second region includes rs6897690 and rs7443175,
which are located in intron 1 and intron 2 in the SPRY4
gene. Indeed the signal we identify is not strong, but it
points to a plausible candidate gene. SPRY4 encodes for a
SPROUTY protein, which is widely expressed, including in
brain.  SPRY4  was identified as the evolutionarily con-
served target of WNT/β-catenin signalling pathway
involved in numerous processes during vertebrate CNS
development.
It is possible that we have missed to detect a stronger asso-
ciation within the 5q31-33 region, as our coverage with
microsatellite markers was still quite sparse and relied on
assumptions about strong uniformly-spread LD. We have
13 intervals with intermarker distance over 300 kb due to
the absence of polymorphic markers, or failure of the cho-
sen ones to be analysed confidently. Therefore, we might
have missed to detect the presence of a disease susceptibil-
ity locus due to the large distance exceeding the assumed
presence of LD between any markers.
Conclusion
In summary, our screening of the 5q31-32 linkage region
using DNA pooling implicates three possible candidate
genes: SMAD5, TGFBI and SPRY4. While none of the find-
ings would survive correction for multiple testing, these
results were found by a systematic analysis of one of the
strongest schizophrenia linkage regions, making them
good candidates to study in other samples, especially sam-
ples that have shown linkage to this region.
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